A Phase 2 interventional study of Obicetrapib in Dyslipidemias, High Cholesterol and Hypercholesterolemia, sponsored by NewAmsterdam Pharma. Completed at 19 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-07-12.
Sponsored by NewAmsterdam Pharma · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 379 studies in Hypercholesterolemia with a site in United States — 32 open to participants now, 42 under way, 11 of them phase 3. Hypercholesterolemia · United States.
Among the 379 studies in Hypercholesterolemia with a site in United States, this one is the 173rd largest by enrollment of the 347 interventional ones that give a count, is one of 16 that started in 2021, is one of 66 in phase 2, and was the 300th registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →32 of the 379 studies in Hypercholesterolemia with a site in United States are open now. Recruiting first, the newest first:
Verve Therapeutics, Inc. · Sites in United States
Ages 18–70
AstraZeneca · Sites in United States, Australia, Canada and 1 more country
Ages 18–130
AstraZeneca · Sites in United States, Bulgaria, Canada and 8 more countries
Ages 18–130
Novartis Pharmaceuticals · Sites in United States
Ages 18–75
Midwest Center for Metabolic and Cardiovascular Research · Sites in United States
Ages 18–74 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
379 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 42 · Phase 2 72 · Phase 3 106 · Phase 4 33
First in 1976; this study’s year is marked. 16 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 120 is close to the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 120 across the 347 interventional studies, 260 across the 31 observational. Of the 319 that completed or were terminated, 161 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
208 of 379 have an industry lead sponsor. The 10 most frequent:
NewAmsterdam Pharma is the lead sponsor of 20 studies on the registry; 3 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 8 (62%) have results posted.
NewAmsterdam Pharma has 7 studies filed under Hypercholesterolemia — fewer than ten, so there is no comparison to draw.
18 of the studies in Hypercholesterolemia with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05030428Phase 3Novartis PharmaceuticalsStudy of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease | 2027-05-10 |
| NCT07619118Phase 3AstraZenecaA Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Rosuvastatin on LDL-C in Patients With Hypercholesterolaemia | 2027-05-28 |
| NCT07619131Phase 3AstraZenecaA Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin and Placebo on LDL-C in LLT-naïve Patients. | 2027-07-30 |
| NCT06960655Brigham and Women's HospitalImproving Lipid Optimization Quality and Treatment Options in ASCVD | 2026-11-30 |
| NCT02694094Johns Hopkins UniversityImpact of Ketogenic Diets on Cardiovascular Health in Adults With Epilepsy | 2026-12 |
Add all 18 to your calendar (.ics) → With an account.
Among the 379 studies in Hypercholesterolemia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will be a placebo-controlled, double-blind, randomized, phase 2 dose-finding study to evaluate the efficacy, safety, and tolerability of obicetrapib as an adjunct to high-intensity statin therapy.
This study will be a placebo-controlled, double-blind, randomized, phase 2 dose-finding study to evaluate the efficacy, safety, and tolerability of obicetrapib as an adjunct to high-intensity statin therapy. The screening period for this study will take up to 2-weeks. Afterwards patients will be randomized to placebo, 5 mg obicetrapib or 10 mg obicetrapib for an 8-week treatment period. After the treatment period, patients will continue for a 4-week safety follow-up and a 15-week PK follow-up.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
This study's enrollment of 120 is close to the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Browse Hypercholesterolemia studies →NewAmsterdam Pharma is the lead sponsor of 20 studies on the registry; 3 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 8 (62%) have results posted.
Compared within Hypercholesterolemia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Dyslipidemias. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
once-daily placebo
Drug: Obicetrapib
once-daily obicetrapib
Drug: Obicetrapib
once-daily obicetrapib
Drug: Obicetrapib
tablets
Also known as: CETP inhibitor
Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) [Friedewald]
Mean percent change from Day 1 to Day 56 in Low-Density Lipoprotein Cholesterol (LDL-C) for each obicetrapib group compared to the placebo group.LDL-C was calculated using the Friedewald equation unless TG ≥400 mg/dL or LDL-C ≤50 mg/dL; if TG ≥400 mg/dL or LDL-C ≤50 mg/dL, then LDL-C level was measured directly by preparative ultracentrifugation (PUC),
Time frame: 8-weeks
Median Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) [Friedewald]
Median Percent change from Day 1 to Day 56 in Low-Density Lipoprotein Cholesterol (LDL-C) for each obicetrapib group compared to the placebo group. \[Friedewald\] LDL-C was calculated using the Friedewald equation unless TG ≥400 mg/dL or LDL-C ≤50 mg/dL; if TG ≥400 mg/dL or LDL-C ≤50 mg/dL, then LDL-C level was measured directly by preparative ultracentrifugation (PUC),
Time frame: 8-Weeks
LS Mean Percent Change Iin Low-Density Lipoprotein Cholesterol (LDL-C) [Friedewald]
LS mean percent change from Day 1 to Day 56 in Low-Density Lipoprotein Cholesterol (LDL-C) for each obicetrapib group compared to the placebo group. \[Friedewald\] LDL-C was calculated using the Friedewald equation unless TG ≥400 mg/dL or LDL-C ≤50 mg/dL; if TG ≥400 mg/dL or LDL-C ≤50 mg/dL, then LDL-C level was measured directly by preparative ultracentrifugation (PUC),
Time frame: 8-Weeks
Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) [PUC]
Mean Percent change from Day 1 to Day 56 in Low-Density Lipoprotein Cholesterol (LDL-C) for each obicetrapib group compared to the placebo group. LDL-C level was measured by preparative ultracentrifugation (PUC).
Time frame: 8-Weeks
Median Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) [PUC]
Median Percent change from Day 1 to Day 56 in Low-Density Lipoprotein Cholesterol (LDL-C) for each obicetrapib group compared to the placebo group. LDL-C level was measured by preparative ultracentrifugation (PUC).
Time frame: 8-Weeks
LS Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) [PUC]
LS Mean Percent change from Day 1 to Day 56 in Low-Density Lipoprotein Cholesterol (LDL-C) for each obicetrapib group compared to the placebo group. LDL-C level was measured directly by preparative ultracentrifugation (PUC).
Time frame: 8-Weeks
Mean Percent Change in Apolipoprotein B (ApoB)
Mean percent change from baseline to Day 56 in apolipoprotein B (ApoB) (mg/dL) for each obicetrapib group compared with the placebo group.
Time frame: 8-Weeks
Median Percent Change in Apolipoprotein B (ApoB)
Median percent change from baseline to Day 56 in apolipoprotein B (ApoB) (mg/dL) for each obicetrapib group compared with the placebo group.
Time frame: 8-Week
LS Mean Percent Change in Apolipoprotein B (ApoB)
Median percent change from baseline to Day 56 in apolipoprotein B (ApoB) (mg/dL) for each obicetrapib group compared with the placebo group.
Time frame: 8-Weeks
Mean Percent Change in Non-high-density Lipoprotein Cholesterol (Non-HDL-C)
Mean percent change from baseline to Day 56 in non-high-density lipoprotein cholesterol (non-HDL-C) (mg/dL) for each obicetrapib group compared with the placebo group
Time frame: 8-weeks
Median Percent Change in Non-high-density Lipoprotein Cholesterol (Non-HDL-C)
Median percent change from baseline to Day 56 in non-high-density lipoprotein cholesterol (non-HDL-C) (mg/dL) for each obicetrapib group compared with the placebo group
Time frame: 8-Weeks
LS Mean Percent Change in Non-high-density Lipoprotein Cholesterol (Non-HDL-C)
LS Mean percent change from baseline to Day 56 in non-high-density lipoprotein cholesterol (non-HDL-C) (mg/dL) for each obicetrapib group compared with the placebo group
Time frame: 8-Weeks
Mean Percent Change in High-density Lipoprotein Cholesterol (HDL-C)
Mean percent change from baseline to Day 56 in High-density lipoprotein cholesterol (HDL-C) (mg/dL) for each obicetrapib group compared with the placebo group.
Time frame: 8-weeks
Median Percent Change in High-density Lipoprotein Cholesterol (HDL-C)
Median percent change from baseline to Day 56 in High-density lipoprotein cholesterol (HDL-C) (mg/dL) for each obicetrapib group compared with the placebo group.
Time frame: 8-Weeks
LS Mean Percent Change in High-density Lipoprotein Cholesterol (HDL-C)
LS mean percent change from baseline to Day 56 in High-density lipoprotein cholesterol (HDL-C) (mg/dL) for each obicetrapib group compared with the placebo group.
Time frame: 8-Weeks
195 participants were screened; out of 195, 120 participants were randomized.
| Milestone | Placebo | Obicetrapib 5 mg | Obicetrapib 10 mg |
|---|---|---|---|
| Started | 40 | 40 | 40 |
| Completed | 39 | 40 | 40 |
| Not completed | 1 | 0 | 0 |
| Withdrew: Adverse event | 1 | 0 | 0 |
Mean percent change from Day 1 to Day 56 in Low-Density Lipoprotein Cholesterol (LDL-C) for each obicetrapib group compared to the placebo group.LDL-C was calculated using the Friedewald equation unless TG ≥400 mg/dL or LDL-C ≤50 mg/dL; if TG ≥400 mg/dL or LDL-C ≤50 mg/dL, then LDL-C level was measured directly by preparative ultracentrifugation (PUC),
| percent change from baseline | Placebo | Obicetrapib 5 mg | Obicetrapib 10 mg |
|---|---|---|---|
| Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) [Friedewald] | -5.48 ± 23.357 | -37.97 ± 27.526 | -43.35 ± 19.369 |
Median Percent change from Day 1 to Day 56 in Low-Density Lipoprotein Cholesterol (LDL-C) for each obicetrapib group compared to the placebo group. \[Friedewald\] LDL-C was calculated using the Friedewald equation unless TG ≥400 mg/dL or LDL-C ≤50 mg/dL; if TG ≥400 mg/dL or LDL-C ≤50 mg/dL, then LDL-C level was measured directly by preparative ultracentrifugation (PUC),
| percent change from baseline | Placebo | Obicetrapib 5 mg | Obicetrapib 10 mg |
|---|---|---|---|
| Median Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) [Friedewald] | 0 (-57.9 to 40.3) | -42.90 (-81.9 to 72.4) | -45.65 (-78.0 to 26.2) |
LS mean percent change from Day 1 to Day 56 in Low-Density Lipoprotein Cholesterol (LDL-C) for each obicetrapib group compared to the placebo group. \[Friedewald\] LDL-C was calculated using the Friedewald equation unless TG ≥400 mg/dL or LDL-C ≤50 mg/dL; if TG ≥400 mg/dL or LDL-C ≤50 mg/dL, then LDL-C level was measured directly by preparative ultracentrifugation (PUC),
| percent change from baseline | Placebo | Obicetrapib 5 mg | Obicetrapib 10 mg |
|---|---|---|---|
| LS Mean Percent Change Iin Low-Density Lipoprotein Cholesterol (LDL-C) [Friedewald] | -5.00 ± 3.502 | -37.97 ± 3.491 | -44.18 ± 3.461 |
Mean Percent change from Day 1 to Day 56 in Low-Density Lipoprotein Cholesterol (LDL-C) for each obicetrapib group compared to the placebo group. LDL-C level was measured by preparative ultracentrifugation (PUC).
| percent change from baseline | Placebo | Obicetrapib 5 mg | Obicetrapib 10 mg |
|---|---|---|---|
| Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) [PUC] | -7.11 ± 20.773 | -35.98 ± 25.469 | -46.06 ± 19.393 |
Median Percent change from Day 1 to Day 56 in Low-Density Lipoprotein Cholesterol (LDL-C) for each obicetrapib group compared to the placebo group. LDL-C level was measured by preparative ultracentrifugation (PUC).
| percent change from baseline | Placebo | Obicetrapib 5 mg | Obicetrapib 10 mg |
|---|---|---|---|
| Median Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) [PUC] | -6.50 (-53.9 to 31.6) | -41.45 (-71.2 to 62.3) | -50.75 (-76.9 to 15.6) |
LS Mean Percent change from Day 1 to Day 56 in Low-Density Lipoprotein Cholesterol (LDL-C) for each obicetrapib group compared to the placebo group. LDL-C level was measured directly by preparative ultracentrifugation (PUC).
| percent change from baseline | Placebo | Obicetrapib 5 mg | Obicetrapib 10 mg |
|---|---|---|---|
| LS Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) [PUC] | -6.70 ± 3.263 | -35.65 ± 3.305 | -46.77 ± 3.225 |
Mean percent change from baseline to Day 56 in apolipoprotein B (ApoB) (mg/dL) for each obicetrapib group compared with the placebo group.
| percent change from baseline | Placebo | Obicetrapib 5 mg | Obicetrapib 10 mg |
|---|---|---|---|
| Mean Percent Change in Apolipoprotein B (ApoB) | -4.67 ± 17.687 | -22.62 ± 21.882 | -27.19 ± 15.329 |
Median percent change from baseline to Day 56 in apolipoprotein B (ApoB) (mg/dL) for each obicetrapib group compared with the placebo group.
| percent change from baseline | Placebo | Obicetrapib 5 mg | Obicetrapib 10 mg |
|---|---|---|---|
| Median Percent Change in Apolipoprotein B (ApoB) | -2.60 (-50.0 to 28.4) | -24.40 (-58.5 to 47.4) | -29.75 (-58.4 to 13.0) |
Median percent change from baseline to Day 56 in apolipoprotein B (ApoB) (mg/dL) for each obicetrapib group compared with the placebo group.
| percent change from baseline | Placebo | Obicetrapib 5 mg | Obicetrapib 10 mg |
|---|---|---|---|
| LS Mean Percent Change in Apolipoprotein B (ApoB) | -4.13 ± 2.593 | -22.40 ± 2.582 | -28.12 ± 2.564 |
Mean percent change from baseline to Day 56 in non-high-density lipoprotein cholesterol (non-HDL-C) (mg/dL) for each obicetrapib group compared with the placebo group
| percent change from baseline | Placebo | Obicetrapib 5 mg | Obicetrapib 10 mg |
|---|---|---|---|
| Mean Percent Change in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) | -4.22 ± 20.440 | -34.28 ± 25.623 | -39.25 ± 17.625 |
Median percent change from baseline to Day 56 in non-high-density lipoprotein cholesterol (non-HDL-C) (mg/dL) for each obicetrapib group compared with the placebo group
| percent change from baseline | Placebo | Obicetrapib 5 mg | Obicetrapib 10 mg |
|---|---|---|---|
| Median Percent Change in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) | -3.50 (-50.3 to 48.4) | -38.90 (-65.6 to 66.3) | -44.40 (-70.2 to 22.5) |
LS Mean percent change from baseline to Day 56 in non-high-density lipoprotein cholesterol (non-HDL-C) (mg/dL) for each obicetrapib group compared with the placebo group
| percent change from baseline | Placebo | Obicetrapib 5 mg | Obicetrapib 10 mg |
|---|---|---|---|
| LS Mean Percent Change in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) | -3.83 ± 3.191 | -34.37 ± 3.179 | -39.86 ± 3.153 |
Mean percent change from baseline to Day 56 in High-density lipoprotein cholesterol (HDL-C) (mg/dL) for each obicetrapib group compared with the placebo group.
| percent change from baseline | Placebo | Obicetrapib 5 mg | Obicetrapib 10 mg |
|---|---|---|---|
| Mean Percent Change in High-density Lipoprotein Cholesterol (HDL-C) | -6.62 ± 12.436 | 123.92 ± 57.671 | 156.41 ± 52.165 |
Median percent change from baseline to Day 56 in High-density lipoprotein cholesterol (HDL-C) (mg/dL) for each obicetrapib group compared with the placebo group.
| percent change from baseline | Placebo | Obicetrapib 5 mg | Obicetrapib 10 mg |
|---|---|---|---|
| Median Percent Change in High-density Lipoprotein Cholesterol (HDL-C) | -4.90 (-30.3 to 28.6) | 135.40 (-26.4 to 212.9) | 164.95 (55.1 to 286.3) |
LS mean percent change from baseline to Day 56 in High-density lipoprotein cholesterol (HDL-C) (mg/dL) for each obicetrapib group compared with the placebo group.
| percent change from baseline | Placebo | Obicetrapib 5 mg | Obicetrapib 10 mg |
|---|---|---|---|
| LS Mean Percent Change in High-density Lipoprotein Cholesterol (HDL-C) | -6.98 ± 6.620 | 122.29 ± 6.585 | 157.35 ± 6.538 |
Collected over From first dose of study drug through week 12. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/40 (0%) | 2/40 (5%) | 17/40 (42.5%) |
| Obicetrapib 5 mg | 0/40 (0%) | 0/40 (0%) | 15/40 (37.5%) |
| Obicetrapib 10 mg | 0/40 (0%) | 0/40 (0%) | 8/40 (20%) |
| Event | Placebo | Obicetrapib 5 mg | Obicetrapib 10 mg |
|---|---|---|---|
| Transient ischemic attackNervous system disorders | 1/40 | 0/40 | 0/40 |
| COVID-19 pneumoniaInfections and infestations | 1/40 | 0/40 | 0/40 |
| Event | Placebo | Obicetrapib 5 mg | Obicetrapib 10 mg |
|---|---|---|---|
| NauseaGastrointestinal disorders | 2/40 | 1/40 | 0/40 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 2/40 | 0/40 | 0/40 |
| Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/40 | 0/40 | 0/40 |
| FatigueGeneral disorders | 2/40 | 2/40 | 1/40 |
| Type 2 diabetes mellitusMetabolism and nutrition disorders | 0/40 | 2/40 | 0/40 |
| HypertensionVascular disorders | 0/40 | 2/40 | 0/40 |
| Pelvic PainReproductive system and breast disorders | 1/40 | 0/40 | 0/40 |
| Abdominal distensionGastrointestinal disorders | 1/40 | 0/40 | 0/40 |
| VomitingGastrointestinal disorders | 1/40 | 0/40 | 0/40 |
| Perineal abscessInfections and infestations | 1/40 | 0/40 | 0/40 |
Baseline Population is defined as all participants who received at least one dose of study drug and had a baseline value for LDL-C assessment.
| Age, Continuous(years) | Placebo | Obicetrapib 5 mg | Obicetrapib 10 mg | Total |
|---|---|---|---|---|
| Mean | 61.3 ± 8.77 | 61.1 ± 8.13 | 62.9 ± 8.48 | 61.8 ± 8.43 |
| Sex: Female, Male(Participants) | Placebo | Obicetrapib 5 mg | Obicetrapib 10 mg | Total |
|---|---|---|---|---|
| Female | 21 | 17 | 15 | 53 |
| Male | 19 | 23 | 25 | 67 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Obicetrapib 5 mg | Obicetrapib 10 mg | Total |
|---|---|---|---|---|
| Hispanic or Latino | 3 | 5 | 6 | 14 |
| Not Hispanic or Latino | 37 | 35 | 34 | 106 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo | Obicetrapib 5 mg | Obicetrapib 10 mg | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 1 | 0 | 5 | 6 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 7 | 10 | 5 | 22 |
| White | 32 | 30 | 30 | 92 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Baseline Low-Density Lipoprotein Cholesterol (LDL-C) Values(milligrams per deciliter (mg/dL)) | Placebo | Obicetrapib 5 mg | Obicetrapib 10 mg | Total |
|---|---|---|---|---|
| Mean | 98.6 ± 31.09 | 99.2 ± 30.95 | 94.2 ± 31.14 | 97.33 ± 31.06 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2021 to primary completion in May 2021, 3 months.
Results were first posted in Jun 2024, 3 years after primary completion.
Of 41 industry-sponsored phase 2 interventional studies under Hypercholesterolemia, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 14. This study's 3 months is below that.
Counting every sponsor, half of 48 studies reached it within 10 months; a quarter within 7 and three quarters within 18.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: TA-8995
NewAmsterdam Pharma